Pelthos Therapeutics (PTHS) Intangibles (2025 - 2026)

Pelthos Therapeutics (PTHS) posted quarterly Intangibles of $39.5 million for Q4 2025, up 21.37% quarter-over-quarter from $32.5 million in Q3 2025.

Pelthos Therapeutics (PTHS) Intangibles (2025 - 2026) Analysis & Trends

Pelthos Therapeutics' Intangibles history runs 1 years deep, the most recent figure standing at $39.5 million for Q4 2025.

In Q4 2025, Intangibles changed N/A year-over-year to $39.5 million; the TTM figure through Dec 2025 stood at $39.5 million (changed N/A YoY), while the FY2025 annual figure was $39.5 million, changed N/A from the prior year.
Intangibles for Q4 2025 stood at $39.5 million, up from $32.5 million in the prior quarter.
The five-year high for Intangibles was $39.5 million in Q4 2025, with the low at $32.5 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Intangibles (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	412.80 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	1.31 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	266.00 Mn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	60.96 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	93.49 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Pelthos Therapeutics	91.09 Mn	66.53 Mn	21.23 Mn	37.40 Mn

Download Data